標題: Titlebook: BRAF Targets in Melanoma; Biological Mechanism Ryan J. Sullivan Book 2015 Springer Science+Business Media New York 2015 BRAF-inhibitors.Nex [打印本頁] 作者: 尤指植物 時間: 2025-3-21 18:05
書目名稱BRAF Targets in Melanoma影響因子(影響力)
書目名稱BRAF Targets in Melanoma影響因子(影響力)學科排名
書目名稱BRAF Targets in Melanoma網絡公開度
書目名稱BRAF Targets in Melanoma網絡公開度學科排名
書目名稱BRAF Targets in Melanoma被引頻次
書目名稱BRAF Targets in Melanoma被引頻次學科排名
書目名稱BRAF Targets in Melanoma年度引用
書目名稱BRAF Targets in Melanoma年度引用學科排名
書目名稱BRAF Targets in Melanoma讀者反饋
書目名稱BRAF Targets in Melanoma讀者反饋學科排名
作者: Eviction 時間: 2025-3-21 21:56
Targeting the Cell Cycle and p53 in Combination with ,-Directed Therapy,d MDM4. The alterations in these pathways appear to play critical roles in the development of melanoma and may represent potential therapeutic targets. Furthermore, some studies suggest that there is interaction between ., key cell cycle proteins and the p53 pathway and that . inhibitors may synergi作者: filial 時間: 2025-3-22 03:46 作者: BILIO 時間: 2025-3-22 06:13
Telecommunications Network Designion of other pro-survival mediators. These findings are now leading to the development of new combinatorial approaches that involve serial and/or parallel blockade strategies in order to overcome resistance mechanisms, and ultimately to improve outcomes in melanoma patients with activating . mutatio作者: GROG 時間: 2025-3-22 09:56 作者: Obedient 時間: 2025-3-22 15:04 作者: Demulcent 時間: 2025-3-22 19:12
Book 2015e previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other typ作者: 激怒某人 時間: 2025-3-22 22:55 作者: STENT 時間: 2025-3-23 03:53
Springer Optimization and Its Applications the discovery of activating B-raf mutations in melanoma, and concluding with the current immune and targeted based therapies for advanced melanoma. It serves as a segue to the more detailed therapies and advances in the ensuing chapters.作者: 整體 時間: 2025-3-23 08:45
Julio López,Marcos J. Rider,Javier Contrerasys. BRAF is the most commonly affected gene, with BRAF(V600E) mutations found in half of all melanomas. The discovery and characterization of oncogenic mutations in the MAPK, RB, p53, and MITF pathways have set the stage for clinically meaningful progress in the melanoma field.作者: Desert 時間: 2025-3-23 13:09
Capacity Assessment in Railway Networks,these two treatment modalities. This chapter focuses on the limitations of each of these strategies as monotherapy, and provides the rationale for combining these therapies. Importantly, ongoing clinical trials of combined BRAF-directed therapy and immunotherapy are discussed, as well as considerations and future directions for therapy.作者: 束以馬具 時間: 2025-3-23 13:58 作者: BILL 時間: 2025-3-23 21:45 作者: 昆蟲 時間: 2025-3-23 22:24 作者: 盟軍 時間: 2025-3-24 04:52
Book 2015ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majo作者: 輪流 時間: 2025-3-24 07:38
2196-9906 ration analytics.Highlights and summarizes the unique biolog?This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-direc作者: laparoscopy 時間: 2025-3-24 12:32
Optimizing Organ Allocation and Acceptance,ions in melanoma tumors. Finally, the application of these techniques with respect to clinical testing is addressed, specifically as they pertain to the development and advancement of personalized medicine.作者: fructose 時間: 2025-3-24 16:01 作者: WAIL 時間: 2025-3-24 20:14
Mauricio G. C. Resende,Panos M. Pardalos issues in oncology trials, such as phase I trials, and early stopping rules are also discussed. The chapter concludes with a case study: Ethical Issues in the BRIM-3 Trial, illustrating key points from this section.作者: 溫和女人 時間: 2025-3-25 02:15 作者: attenuate 時間: 2025-3-25 06:08 作者: Parameter 時間: 2025-3-25 10:42 作者: 散開 時間: 2025-3-25 12:27 作者: harpsichord 時間: 2025-3-25 18:23 作者: 開始從未 時間: 2025-3-25 20:33 作者: 危險 時間: 2025-3-26 03:27 作者: 使絕緣 時間: 2025-3-26 05:30 作者: Conscientious 時間: 2025-3-26 11:35
Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma,atalytic activity and its downstream effectors in the RAS-RAF-MEK-ERK signaling pathway. Both selective BRAF and MEK inhibitors have demonstrated high clinical response rates in metastatic melanoma patients with activating . mutations. These successes have illustrated several keys to the successful 作者: 撫慰 時間: 2025-3-26 16:25 作者: Charade 時間: 2025-3-26 20:28 作者: 亞麻制品 時間: 2025-3-26 22:07
Moving Forward: Making BRAF-Targeted Therapy Better,for developing molecularly targeted therapy combinations. The clinical utility of vemurafenib, FDA approved BRAF inhibitor, has been validated by another potent and selective agent, dabrafenib. However, two clinical limitations of BRAF inhibitor therapy frame the problem for the melanoma field: . an作者: pantomime 時間: 2025-3-27 04:19 作者: flamboyant 時間: 2025-3-27 09:02 作者: 充足 時間: 2025-3-27 09:48
Optimizing Organ Allocation and Acceptance,revalent mutation being the . V600 mutation. Targeted inhibitors directed against this mutation have produced improved overall survival compared to chemotherapy. Multiple additional somatic mutations have been identified, and some also have prompted the development of therapy targeted against them. 作者: LIKEN 時間: 2025-3-27 14:08 作者: 沉著 時間: 2025-3-27 18:12 作者: 投票 時間: 2025-3-27 22:37
Telecommunications Network Designatalytic activity and its downstream effectors in the RAS-RAF-MEK-ERK signaling pathway. Both selective BRAF and MEK inhibitors have demonstrated high clinical response rates in metastatic melanoma patients with activating . mutations. These successes have illustrated several keys to the successful 作者: Vo2-Max 時間: 2025-3-28 04:09
Giorgio Medeossi,Stefano de Fabrisrates for systemic treatments for metastatic melanoma were only 5–20?% for chemotherapy, and the prognosis of patients with metastatic disease was extremely poor. The discovery of . mutations in melanoma led to the development of .-directed therapy which dramatically increased response rates. Howeve作者: 加入 時間: 2025-3-28 07:06
Capacity Assessment in Railway Networks,erapy. Both of these classes of therapy demonstrate survival benefit, but also have limitations as monotherapy with regard to overall response rate and/or durability of response. We have gained significant insight into mechanisms of response to BRAF-directed therapy and to potential synergy between 作者: Surgeon 時間: 2025-3-28 12:48 作者: ABYSS 時間: 2025-3-28 15:19 作者: 魅力 時間: 2025-3-28 22:15 作者: 藥物 時間: 2025-3-29 02:13
